FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1997013532> ?p ?o ?g. }

• W1997013532 endingPage "82" @default.
• W1997013532 startingPage "75" @default.
• W1997013532 abstract "<i>Background:</i> This phase II trial was conducted to determine the activity and safety of the combination of fixed-dose rate (FDR) gemcitabine and capecitabine in metastatic biliary tract cancer (BTC) patients. <i>Methods:</i> Patients with unresectable BTC who had pathologically confirmed adenocarcinoma, no prior chemotherapy, Eastern Cooperative Oncology Group (ECOG) performance status ≤1 and measurable disease were enrolled. Treatment consisted of FDR gemcitabine at 800 mg/m² on days 1 and 8 every 21 days with capecitabine administered orally b.i.d. in equal doses (650 mg/m² b.i.d.) for 14 days (28 doses). <i>Results:</i> Between May 2005 and February 2009, 30 patients were enrolled. The median age was 67 years (45–76) and there were 14 males. Thirty patients were evaluable for response and toxicity. A total of 221 cycles were administered (median 7, range 2–16). One patient achieved complete response and 7 patients achieved partial response, giving an overall response rate of 26.7% in the intention-to-treat population. Twelve patients (40.0%) had stable disease. The median progression-free survival was 6.33 months. The median overall survival was 10.8 months. Grade 3/4 neutropenia and thrombocytopenia were noted in 13 and 7% of the patients, respectively. Grade 2/3 nonhematologic toxicities were asthenia (54% of patients), diarrhea (17%), stomatitis (23%) and hand-foot syndrome (7%). There was no treatment-related death. The drugs taken were skipped at least once in 45% of the patients and the dose was reduced in 26% of them. <i>Conclusions:</i> The combination of FDR gemcitabine and capecitabine in this 3-week cycle is safe and seems to have a good activity in advanced biliary cancer." @default.
• W1997013532 created "2016-06-24" @default.
• W1997013532 creator A5004175335 @default.
• W1997013532 creator A5017866134 @default.
• W1997013532 creator A5018141422 @default.
• W1997013532 creator A5025063054 @default.
• W1997013532 creator A5029788016 @default.
• W1997013532 creator A5038347927 @default.
• W1997013532 creator A5047673996 @default.
• W1997013532 creator A5058514609 @default.
• W1997013532 creator A5059367989 @default.
• W1997013532 creator A5081470600 @default.
• W1997013532 creator A5082066847 @default.
• W1997013532 date "2012-01-01" @default.
• W1997013532 modified "2023-10-17" @default.
• W1997013532 title "A Phase II Trial of Fixed-Dose Rate Gemcitabine plus Capecitabine in Metastatic/Advanced Biliary Tract Cancer Patients" @default.
• W1997013532 cites W138827541 @default.
• W1997013532 cites W1890647543 @default.
• W1997013532 cites W1911108481 @default.
• W1997013532 cites W1931508686 @default.
• W1997013532 cites W1968773418 @default.
• W1997013532 cites W1970545762 @default.
• W1997013532 cites W1989236133 @default.
• W1997013532 cites W1996520070 @default.
• W1997013532 cites W2001563940 @default.
• W1997013532 cites W2007700830 @default.
• W1997013532 cites W2019438357 @default.
• W1997013532 cites W2025769688 @default.
• W1997013532 cites W2044970916 @default.
• W1997013532 cites W2049703514 @default.
• W1997013532 cites W2065756402 @default.
• W1997013532 cites W2067892704 @default.
• W1997013532 cites W2073346844 @default.
• W1997013532 cites W2074764208 @default.
• W1997013532 cites W2075656484 @default.
• W1997013532 cites W2078750212 @default.
• W1997013532 cites W2084012824 @default.
• W1997013532 cites W2093388808 @default.
• W1997013532 cites W2094501197 @default.
• W1997013532 cites W2101036284 @default.
• W1997013532 cites W2103529483 @default.
• W1997013532 cites W2113222623 @default.
• W1997013532 cites W2115261608 @default.
• W1997013532 cites W2117050193 @default.
• W1997013532 cites W2117834374 @default.
• W1997013532 cites W2118520585 @default.
• W1997013532 cites W2128719076 @default.
• W1997013532 cites W2128889451 @default.
• W1997013532 cites W2136797122 @default.
• W1997013532 cites W2137194656 @default.
• W1997013532 cites W2137481060 @default.
• W1997013532 cites W2139947970 @default.
• W1997013532 cites W2161810289 @default.
• W1997013532 cites W2164008260 @default.
• W1997013532 cites W2188928518 @default.
• W1997013532 cites W2332605220 @default.
• W1997013532 doi "https://doi.org/10.1159/000329079" @default.
• W1997013532 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22327844" @default.
• W1997013532 hasPublicationYear "2012" @default.
• W1997013532 type Work @default.
• W1997013532 sameAs 1997013532 @default.
• W1997013532 citedByCount "7" @default.
• W1997013532 countsByYear W19970135322012 @default.
• W1997013532 countsByYear W19970135322013 @default.
• W1997013532 countsByYear W19970135322014 @default.
• W1997013532 countsByYear W19970135322018 @default.
• W1997013532 countsByYear W19970135322021 @default.
• W1997013532 crossrefType "journal-article" @default.
• W1997013532 hasAuthorship W1997013532A5004175335 @default.
• W1997013532 hasAuthorship W1997013532A5017866134 @default.
• W1997013532 hasAuthorship W1997013532A5018141422 @default.
• W1997013532 hasAuthorship W1997013532A5025063054 @default.
• W1997013532 hasAuthorship W1997013532A5029788016 @default.
• W1997013532 hasAuthorship W1997013532A5038347927 @default.
• W1997013532 hasAuthorship W1997013532A5047673996 @default.
• W1997013532 hasAuthorship W1997013532A5058514609 @default.
• W1997013532 hasAuthorship W1997013532A5059367989 @default.
• W1997013532 hasAuthorship W1997013532A5081470600 @default.
• W1997013532 hasAuthorship W1997013532A5082066847 @default.
• W1997013532 hasBestOaLocation W19970135322 @default.
• W1997013532 hasConcept C121608353 @default.
• W1997013532 hasConcept C126322002 @default.
• W1997013532 hasConcept C141071460 @default.
• W1997013532 hasConcept C2776694085 @default.
• W1997013532 hasConcept C2777063308 @default.
• W1997013532 hasConcept C2777909004 @default.
• W1997013532 hasConcept C2780258809 @default.
• W1997013532 hasConcept C2908647359 @default.
• W1997013532 hasConcept C31760486 @default.
• W1997013532 hasConcept C526805850 @default.
• W1997013532 hasConcept C71924100 @default.
• W1997013532 hasConcept C90924648 @default.
• W1997013532 hasConcept C99454951 @default.
• W1997013532 hasConceptScore W1997013532C121608353 @default.
• W1997013532 hasConceptScore W1997013532C126322002 @default.
• W1997013532 hasConceptScore W1997013532C141071460 @default.
• W1997013532 hasConceptScore W1997013532C2776694085 @default.
• W1997013532 hasConceptScore W1997013532C2777063308 @default.

• next